At just certified CE, medtech neuroClues is already rolling out deployments across Europe and announcing a €10 million Series A round, aiming to establish its ocular biomarkers as a new clinical standard. Behind the technological promise, neuroClues highlights what it sees as decades of delay in neurological diagnostic methods.
- neuroClues is integrated into major clinical cohorts, notably at the Brain Institute in Paris.
- The company is participating in a mega-cohort of 25,000 patients to build a large-scale normative database.
- It is also developing international partnerships, particularly in India with AIIMS.
neuroClues integrates AI into neurological diagnosis
The assessment made by neuroClues is unequivocal: the clinical evaluation of neurological diseases has barely evolved in more than 60 years. Yet, in the context of an ageing population, neurodegenerative diseases are rising sharply, with worrying projections, particularly for Parkinson’s disease.
Even today, one in five patients is reportedly misdiagnosed. And by the time a diagnosis is finally made, the damage is often already considerable, with an estimated 65% loss of the affected neurons. This delay carries major consequences, both for patients and for healthcare systems.
This gap is largely explained by clinical practices that have remained highly subjective. Neurologists still rely heavily on observational tests such as “follow my finger,” due to the lack of accessible and reliable quantitative tools. Advanced technologies do exist, but they remain expensive, limited in availability, and often ineffective at detecting diseases in their early stages.
It is precisely to address late diagnosis, prolonged care pathways, and healthcare resources being used without optimal efficiency that neuroClues was created, focusing on the objective measurement of clinical data.
A technological promise: bringing objective measurement to neurology in just 10 minutes
The solution developed by neuroClues is based on a seemingly simple principle: analyzing eye movements to extract neurological biomarkers. In practice, the company relies on a portable Class IIa medical device, now CE-marked, capable of delivering results within minutes.
In practical terms, the device captures high-speed infrared images of the patient’s eyes while they perform simple visual tasks. This data is then processed using proprietary artificial intelligence algorithms, generating objective and reproducible indicators. Its ambition is to replace subjective assessments with standardized measurements that can be directly used during consultations. The device integrates seamlessly into clinical workflows, without major constraints, and even enables remote interpretation. This approach aims to drastically reduce analysis times.
In the long term, the platform aims to go even further. By accumulating large-scale data, it seeks to identify certain conditions more precisely: differentiating between types of parkinsonism, enabling earlier detection of Alzheimer’s disease, and identifying the consequences of concussions. A promise that ultimately depends on the robustness of the data collected.
Commercial acceleration backed by a strategic funding round
Just months after obtaining CE certification in January 2025, neuroClues already reports a presence in seven European countries. More than 30 devices have been deployed across hospitals, private practices, and research centers, reflecting growing interest from the field.
This commercial traction is notably supported by:
- Integration into major clinical cohorts, including those at the Brain Institute in Paris
- Participation in a mega-cohort of 25,000 patients to build a normative database
- Selection by acceleration programs such as Bpifrance and PariSanté Campus
- Expansion of international partnerships, notably in India with AIIMS
To support this momentum, the company has announced a €10 million Series A funding round led by Teampact Ventures, White Fund, and the EIC Fund. Including additional non-dilutive financing, the total amount raised now stands at €25 million.
Beyond funding, neuroClues says it is structuring its growth with the appointment of Bart Stulens, formerly of Medtronic, as EMEA Commercial Director. Behind this hire, the medtech company aims to industrialize its European rollout while preparing for expansion into the United States.
At the same time, the company is opening a €1.5 million investment round through the LITA platform, making participation accessible to private investors. This remains relatively uncommon at this stage of maturity and reflects both a desire to encourage citizen involvement and a need for additional financing. It remains to be seen whether this approach will genuinely help democratize innovation.
Published by the Editorial Staff on